Shared Monopoly in sale of generic Revlimid: Dr Reddy's Labs, Bristol Myers Squibb and others face anti-trust litigation in US
The company said the complaint "alleges that the challenged agreements improperly delayed generic entry entirely until 2022 and then improperly limited generic competition through 2026."
New Delhi: Pharma major Dr Reddy's Laboratories Ltd on Tuesday said it is among several generic pharmaceutical companies, including Celgene and Bristol Myers Squibb, against which an antitrust litigation has been filed in the US. In a regulatory filing, the company said a complaint was filed on November 18, 2022, in the District of New Jersey, USA, and it along with other generic pharmaceutical firms have been named as defendants.
Read also: Dr Reddy's Labs unveils cancer drug Lenalidomide in US
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddys beats Aurobindo Pharma to become second biggest drug maker in India: Report
